BioCryst Pharmaceuticals Company Profile (NASDAQ:BCRX)

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its quarterly earnings results on Monday, August, 7th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.02. The business earned $3.10 million during the quarter, compared to analysts' expectations of $5.79 million. BioCryst Pharmaceuticals had a negative return on equity of 276.62% and a negative net margin of 160.97%. BioCryst Pharmaceuticals's revenue for the quarter was down 35.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.22) EPS. View BioCryst Pharmaceuticals' Earnings History.

BioCryst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for BioCryst Pharmaceuticals.

10 brokers have issued 1 year price objectives for BioCryst Pharmaceuticals' shares. Their forecasts range from $6.00 to $15.00. On average, they anticipate BioCryst Pharmaceuticals' share price to reach $9.25 in the next year. View Analyst Ratings for BioCryst Pharmaceuticals.

Here are some recent quotes from research analysts about BioCryst Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. " (8/10/2017)
• 2. Needham & Company LLC analysts commented, "Shire (SHPG) reported positive results from the ph 3 HELP trial evaluating lanadelumab (fka SHP643) as a prophylactic HAE treatment. Lanadelumab, an antibody that binds and inhibits plasma kallikrein, is formulated for subcutaneous administration and has a long half-life (~14 days) that enables once- or twice-monthly dosing. The HELP trial met all of its endpoints; monthly attack rate reduction vs. placebo for all dosing regimens ranged from 73% – 87% (p<0.001). A BLA filing for lanadelumab is expected in late-2017/early-2018. BCRX's BCX7353, a daily orally-administered HAE prophylactic candidate, is currently under evaluation in the ph 2 APeX-1 trial. Positive interim results reported in late-Feb showed that BCX7353 led to a ~52% HAE attack rate reduction (p=0.035, ITT), with results showing a dichotomy of efficacy between peripheral attacks (~88% reduction) and abdominal attacks (~24% reduction). Additional APeX-1 cohorts evaluating lower-doses of BCX7353 are expected to report in 2Q17. These data should provide clarity on the efficacy/tolerability profile of BCX7353 and help shed some light on its potential role in HAE prophylaxis."" (5/19/2017)

Some companies that are related to BioCryst Pharmaceuticals include Five Prime Therapeutics (FPRX), Xencor (XNCR), NeuroDerm (NDRM), Omeros Corporation (OMER), Athenex (ATNX), Ascendis Pharma A/S (ASND), REGENXBIO (RGNX), ZIOPHARM Oncology (ZIOP), Retrophin (RTRX), Amarin Corporation PLC (AMRN), Intra-Cellular Therapies (ITCI), Keryx Biopharmaceuticals (KERX), PTC Therapeutics (PTCT), Reata Pharmaceuticals (RETA), Aduro Biotech (ADRO), Vanda Pharmaceuticals (VNDA), Akebia Therapeutics (AKBA) and Flexion Therapeutics (FLXN).

BioCryst Pharmaceuticals' management team includes the folowing people:

• Robert A. Ingram, Chairman of the Board
• Jon P. Stonehouse, President, Chief Executive Officer, Director
• Thomas R. Staab II, Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer
• Yarlagadda S. Babu Ph.D., Senior Vice President - Drug Discovery
• Lynne M Powell, Senior Vice President, Chief Commercial Officer
• William P. Sheridan, Senior Vice President, Chief Medical Officer
• Alane P. Barnes, Vice President, General Counsel, and Corporate Secretary
• Fred E. Cohen Ph.D. M.D., Director
• Sanj K. Patel, Director
• George B. Abercrombie, Independent Director

BioCryst Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.47%), RA Capital Management LLC (6.42%), State Street Corp (4.86%), FMR LLC (3.89%), VHCP Management II LLC (3.08%) and Jennison Associates LLC (2.59%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Bros Advisors Lp Baker, Fred E Cohen, Thomas R Staab II and Yarlagadda S Babu. View Institutional Ownership Trends for BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Federated Investors Inc. PA, JPMorgan Chase & Co., Emory University, Schwab Charles Investment Management Inc., Wells Fargo & Company MN, California State Teachers Retirement System and Dynamic Technology Lab Private Ltd. Company insiders that have sold BioCryst Pharmaceuticals stock in the last year include Fred E Cohen and Thomas R Staab II. View Insider Buying and Selling for BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management LLC, FMR LLC, State Street Corp, Vanguard Group Inc., Artal Group S.A., Jennison Associates LLC, OxFORD Asset Management LLP and TIAA CREF Investment Management LLC. View Insider Buying and Selling for BioCryst Pharmaceuticals.

Shares of BioCryst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of BioCryst Pharmaceuticals stock can currently be purchased for approximately $5.43.